search
Back to results

TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality

Primary Purpose

Coronary Artery Disease

Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Inhalational anesthetic
Intravenous anesthetic, propofol
Sponsored by
University Hospital, Basel, Switzerland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Coronary Artery Disease focused on measuring preconditioning, cardiac protection, morbidity, mortality, major non-cardiac surgery, cardiac mortality and morbidity, high cardiac perioperative risk

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients scheduled for a non-cardiac surgical procedure of high or intermediate cardiac risk are eligible if they have documented coronary artery disease (CAD) or are at high risk of CAD. Exclusion Criteria: Ongoing medication with sulfonylurea derivatives (unless stopped ≥ 2 days before surgery) or theophylline Emergency surgery Unstable angina pectoris Preoperative hemodynamic instability Severe hepatic disease Renal insufficiency (creatinine clearance < 30 ml/min) Severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second [FEV1] < 1 litre) Absence of written patient consent

Sites / Locations

  • Kantonsspital
  • University Hospital
  • Bürgerspital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Inhalational anesthetic

Intravenous anesthetic, propofol

Arm Description

Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered

Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered

Outcomes

Primary Outcome Measures

Ischemia (Holter-electrocardiogram [ECG], troponin T, ECG)

Secondary Outcome Measures

Congestive heart failure (N-terminal B-type natriuretic peptide [NT-pro-BNP])
influence of genetic polymorphism on cardiac morbidity and mortality
cardiac morbidity and mortality

Full Information

First Posted
February 2, 2006
Last Updated
August 24, 2012
Sponsor
University Hospital, Basel, Switzerland
Collaborators
Abbott
search

1. Study Identification

Unique Protocol Identification Number
NCT00286585
Brief Title
TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality
Official Title
Multi-Center Trial on the Effect of Anesthetics on Morbidity and Mortality in Patients Undergoing Major Non-cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
Abbott

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Volatile anesthetics may provide some protection from myocardial ischemia, an effect called anesthetic preconditioning. In patients undergoing coronary artery bypass surgery, this preconditioning effect resulted in better cardiac performance, faster recovery and lower morbidity and mortality. The investigators will perform a prospective randomized multi-center study to compare volatile with total intravenous anesthesia in patients at a high cardiac risk who undergo major non-cardiac surgery.
Detailed Description
Basic research and animal studies have detected that volatile anesthetics provide some protection from myocardial ischemia, an effect called anesthetic preconditioning. Recent clinical studies have found that this preconditioning effect is of clinical relevance in patients undergoing coronary artery bypass surgery, resulting in better cardiac function and faster recovery after surgery, and in lower one-year morbidity. In patients undergoing non cardiac surgery, cardiac complications also are the major cause of perioperative morbidity and mortality. Myocardial ischemia frequently occurs during and immediately after non cardiac surgery in patients with coronary artery disease, and is a strong predictor of subsequent cardiac complications and death. Whether or not volatile anesthetics also provide clinically relevant protection from perioperative ischemia and subsequent cardiac complications in patients undergoing non cardiac surgery is unknown. Therefore, we will perform a prospective, randomized multi-center study to compare volatile with total intravenous anesthesia in patients at high cardiac risk who undergo major non cardiac surgery. We hypothesize that the use of a volatile anesthetic will reduce the incidence of perioperative ischaemia and myocardial injury, as indicated primarily by less ST-segment changes in the Holter ECG and, if there will be an effect, secondarily by lower incidences of elevated troponin T and NT-pro-BNP levels. And we hypothesize that the use of a volatile anesthetic will reduce the one-year incidence of cardiac complications and all cause mortality after surgery. The results of this study may apply to a huge percentage of surgical patients because coronary artery disease is the clinically most relevant co-morbidity, and its prevalence is expected to increase with the steadily increasing number of surgical patients aged 65 yr and older.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
preconditioning, cardiac protection, morbidity, mortality, major non-cardiac surgery, cardiac mortality and morbidity, high cardiac perioperative risk

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
385 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inhalational anesthetic
Arm Type
Active Comparator
Arm Description
Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
Arm Title
Intravenous anesthetic, propofol
Arm Type
Active Comparator
Arm Description
Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
Intervention Type
Drug
Intervention Name(s)
Inhalational anesthetic
Other Intervention Name(s)
Ultane,, Sevorane
Intervention Description
Sevoflurane, dosage according to the physician in charge
Intervention Type
Drug
Intervention Name(s)
Intravenous anesthetic, propofol
Other Intervention Name(s)
Diprivan,, Diprovan
Intervention Description
Propofol, dosage according to the physician in charge
Primary Outcome Measure Information:
Title
Ischemia (Holter-electrocardiogram [ECG], troponin T, ECG)
Time Frame
7 days postoperatively
Secondary Outcome Measure Information:
Title
Congestive heart failure (N-terminal B-type natriuretic peptide [NT-pro-BNP])
Time Frame
2 days postoperatively
Title
influence of genetic polymorphism on cardiac morbidity and mortality
Time Frame
7 days, 6 and 12 months
Title
cardiac morbidity and mortality
Time Frame
6 and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients scheduled for a non-cardiac surgical procedure of high or intermediate cardiac risk are eligible if they have documented coronary artery disease (CAD) or are at high risk of CAD. Exclusion Criteria: Ongoing medication with sulfonylurea derivatives (unless stopped ≥ 2 days before surgery) or theophylline Emergency surgery Unstable angina pectoris Preoperative hemodynamic instability Severe hepatic disease Renal insufficiency (creatinine clearance < 30 ml/min) Severe chronic obstructive pulmonary disease (forced expiratory volume in 1 second [FEV1] < 1 litre) Absence of written patient consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manfred Seeberger, Prof. Dr.
Organizational Affiliation
Department of Anesthesia, University Hospital, Basel, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kantonsspital
City
Liestal
State/Province
Basel-Land
ZIP/Postal Code
CH-4410
Country
Switzerland
Facility Name
University Hospital
City
Basel
ZIP/Postal Code
CH-4000
Country
Switzerland
Facility Name
Bürgerspital
City
Solothurn
ZIP/Postal Code
CH-4500
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
27870734
Citation
Mauermann E, Bolliger D, Seeberger E, Puelacher C, Corbiere S, Filipovic M, Seeberger M, Mueller C, Lurati Buse G. Incremental Value of Preoperative Copeptin for Predicting Myocardial Injury. Anesth Analg. 2016 Dec;123(6):1363-1371. doi: 10.1213/ANE.0000000000001635.
Results Reference
derived
PubMed Identifier
23136158
Citation
Lurati Buse GA, Schumacher P, Seeberger E, Studer W, Schuman RM, Fassl J, Kasper J, Filipovic M, Bolliger D, Seeberger MD. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation. 2012 Dec 4;126(23):2696-704. doi: 10.1161/CIRCULATIONAHA.112.126144. Epub 2012 Nov 7.
Results Reference
derived

Learn more about this trial

TEAM-Project: Trial on the Effect of Anesthetics on Morbidity and Mortality

We'll reach out to this number within 24 hrs